Thursday, July 26, 2012

Genentech's Lucentis recommended for approval for diabetic eye disease

An FDA advisory panel recommended Thursday that Genentech Inc.'s eye drug Lucentis be approved for some diabetes patients who have lost their sight. Already approved for age-related macular degeneration, Lucentis' approved use could extend to patients with diabetic macular degeneration if the Food and Drug Administration approves the new application by Aug. 10.

No comments:

Post a Comment